MedTrace Logo

Predictive Factors for Resection and Survival in Type A Borderline Resectable Pancreatic Ductal Adenocarcinoma Patients After Neoadjuvant Therapy

NCT05489458 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2022-08-05

No results posted yet for this study

Summary

Radical surgical resection is the only curative treatment option for pancreatic cancer, but borderline resectable tumors have a high probability of incomplete exeresis. Although neoadjuvant therapy can improve the chances of complete exeresis, not all patients respond as expected.

Conditions

  • Carcinoma, Pancreatic Ductal

Interventions

PROCEDURE

Resection

Type A BR-PDAC patients who had a favorable tumor/vascular structures relationship confirmed during surgical exploration underwent resection.

PROCEDURE

No Resection

Type A BR-PDAC patients who did not have a favorable tumor/vascular structures relationship confirmed during surgical exploration did not undergo resection.

Sponsors & Collaborators

  • BUSQUETS, JULI

    lead OTHER

Principal Investigators

  • Luis Secanella, MD · Bellvitge University Hospital

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-09-30
Primary Completion
2022-10-31
Completion
2023-01-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05489458 on ClinicalTrials.gov